KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Total Liabilities (2018 - 2026)

Amneal Pharmaceuticals has reported Total Liabilities over the past 8 years, most recently at $3.7 billion for Q4 2025.

  • For Q4 2025, Total Liabilities rose 3.85% year-over-year to $3.7 billion; the TTM value through Dec 2025 reached $3.7 billion, up 3.85%, while the annual FY2025 figure was $3.7 billion, 3.85% up from the prior year.
  • Total Liabilities for Q4 2025 was $3.7 billion at Amneal Pharmaceuticals, up from $3.7 billion in the prior quarter.
  • Over five years, Total Liabilities peaked at $3.9 billion in Q2 2022 and troughed at $3.5 billion in Q4 2023.
  • A 5-year average of $3.6 billion and a median of $3.6 billion in 2021 define the central range for Total Liabilities.
  • Biggest five-year swings in Total Liabilities: dropped 9.88% in 2021 and later rose 6.49% in 2022.
  • Year by year, Total Liabilities stood at $3.6 billion in 2021, then increased by 1.19% to $3.6 billion in 2022, then fell by 4.5% to $3.5 billion in 2023, then rose by 4.58% to $3.6 billion in 2024, then grew by 3.85% to $3.7 billion in 2025.
  • Business Quant data shows Total Liabilities for AMRX at $3.7 billion in Q4 2025, $3.7 billion in Q3 2025, and $3.5 billion in Q2 2025.